Clinical Report: Erratum on Authorship and Funding Details in SGLT2 Inhibitors Study

Overview

This erratum addresses corrections in the authorship roster and funding section of the original article on the impact of SGLT2 inhibitors on anemia in type 2 diabetes patients. Specifically, hyphens were added to the last names of two authors to accurately reflect their names.

Background

The original article investigated the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on anemia among patients with type 2 diabetes using real-world data. Accurate authorship and funding information are essential for transparency and proper attribution in clinical research. This correction ensures the proper representation of author names and funding acknowledgments.

Data Highlights

No numerical data or study results are presented in this erratum; it solely addresses corrections to author names and funding details.

Key Findings

• The hyphen was omitted in author Benaya Rozen-Zvi’s last name and has now been corrected.
• The hyphen was omitted in author Anat Gafter-Gvili’s last name and has now been corrected.
• The Funding section also contained the incorrect spelling of Benaya Rozen-Zvi’s name, which has been corrected.
• The article has been updated online to reflect these corrections.

Clinical Implications

While this erratum does not impact clinical findings, it highlights the importance of accurate author identification and funding disclosure in clinical publications. Proper attribution supports research integrity and accountability.

Conclusion

The corrections to author names and funding details have been made to the original article to ensure accurate representation and transparency in the published research.

References

1. Steinmetz et al. 2025 -- Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Anemia in Patients with Type 2 Diabetes